ibi351

Colorectal Cancer

Innovent Biologics (Suzhou) Co. Ltd.Phase 1Active

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 59/ 100

Competitive context

839 Active assets in the Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
FLUOROURACILUM Washington University School of Medicine	Phase 4	BB
PANITUMUMAB M.D. Anderson Cancer Center	Phase 3	BB
Cetuximab Shanghai Henlius Biotech	Phase 4	BB

View all 50 →

Same molecule, other indications

ibi351 is also rated in:

non-small cell lung carcinomaDormant

B

Indicative ·

58 / 100

KRAS G12C MutationDormant

CCC

Indicative ·

53 / 100

Colorectal Cancer MetastaticDormant

CCC

Indicative ·

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.